Cyclerion Therapeutics, Inc.
CYCN
$3.13
-$0.05-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.41% | 58.36% | 57.31% | 60.31% | 76.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.32% | 92.59% | -73.29% | -70.59% | -71.15% |
| Change in Net Operating Assets | 85.24% | 129.77% | -135.05% | 78.80% | 35.62% |
| Cash from Operations | 23.52% | 77.94% | 37.43% | 65.59% | 69.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 63.90% | -29.60% | -30.45% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 97.40% | 97.40% | -- | -- |
| Cash from Financing | -- | -- | -- | -72.63% | -- |
| Foreign Exchange rate Adjustments | -- | 100.00% | 100.00% | -166.67% | -175.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.18% | 127.20% | 65.00% | 58.36% | 53.23% |